Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProscaVax
- Development stage
- Unknown
- Lead developer
- OncBioMune Pharmaceuticals
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
**ProscaVax** is an investigational therapeutic cancer vaccine developed by OncBioMune Pharmaceuticals for prostate cancer. The product combines prostate-specific antigen with the immunostimulatory cytokines interleukin-2 and granulocyte-macrophage colony-stimulating factor. It is intended to induce PSA-directed antitumor immune responses while IL-2 supports T-cell activation and proliferation and GM-CSF promotes antigen-presenting-cell recruitment and activation. ProscaVax has been evaluated by intradermal administration in patients with PSA-recurrent hormone-naive or hormone-independent prostate cancer and in a Phase 2 study in treatment-naive clinically localized prostate cancer managed with active surveillance.
- Brand names
- ProscaVax
- Other names
- PSA/IL-2/GM-CSF vaccineprostate-specific antigen + interleukin-2 + granulocyte-macrophage colony-stimulating factor
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on ProscaVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProscaVax.